Patient demographic characteristics |  | Asthma (n = 201) | COPD (n = 93) | Total (n = 294) |
---|---|---|---|---|
Age | Mean (SD) | 40.30 (13.44) | 48.48 (15.16) | 42.89 (14.49) |
Gender | Male | 63 (31.34%) | 42 (45.16%) | 105 (35.71%) |
Female | 138 (68.66%) | 51 (54.84%) | 189 (64.29%) | |
Current inhaler | Symbicort Turbuhaler | 95 (47%) | 44 (47%) | 139 (47%) |
Seretide Diskus | 106 (53%) | 49 (53%) | 155 (53%) | |
Revenue in last 12 months | <€22,500 | 97 (48.26%) | 40 (43.01%) | 137 (46.60%) |
€25,000–€34,999 | 39 (19.40%) | 14 (15.05%) | 53 (18.03%) | |
€35,000–€49,999 | 30 (14.93%) | 15 (16.13%) | 45 (15.31%) | |
€50,000–€74,999 | 15 (7.46%) | 7 (7.53%) | 22 (7.48%) | |
€75,000+ | 2 (1.00%) | 6 (6.45%) | 8 (2.72%) | |
No answer | 18 (8.96%) | 11 (11.83%) | 29 (9.86%) | |
Costs associated with asthma and COPD treatment (€)/month | Mean (SD) | 11.89 (21.93) | 22.11 (37.37) | 15.12 (28.10) |
HUI3 | Mean (SD) | 0.71 (0.25) | 0.54 (0.30) | 0.66 (0.28) |